VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

John Copland on Patient-Derived Xenografts in Anaplastic Thyroid Cancer

John Copland, PhD
Published: Tuesday, Oct 27, 2015



John Copland, PhD, faculty member in the department of cancer biology, Mayo Clinic, explains his research on patient-derived xenograft (PDX) models in anaplastic thyroid cancer.

Anaplastic thyroid cancer has approximately a four to six-month median survival rate, and is one of the deadliest forms of cancer, says Copland. It is also a rare cancer, making it difficult to conduct clinical trials.

PDX models are developed using surgical tissue from patients that is implanted into immune-incompetent mice. Once the tumor has grown, various therapies and therapeutic combinations can be tested in each mouse model. These models are highly predictive of patient response, says Copland.

This technique could make it possible to create personalized treatments based on response rates in PDX models. Future patients with similar tumors could also benefit.



John Copland, PhD, faculty member in the department of cancer biology, Mayo Clinic, explains his research on patient-derived xenograft (PDX) models in anaplastic thyroid cancer.

Anaplastic thyroid cancer has approximately a four to six-month median survival rate, and is one of the deadliest forms of cancer, says Copland. It is also a rare cancer, making it difficult to conduct clinical trials.

PDX models are developed using surgical tissue from patients that is implanted into immune-incompetent mice. Once the tumor has grown, various therapies and therapeutic combinations can be tested in each mouse model. These models are highly predictive of patient response, says Copland.

This technique could make it possible to create personalized treatments based on response rates in PDX models. Future patients with similar tumors could also benefit.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x